News about Clinical Trials

GC Biopharma's Anthrax Vaccine Shows Safety and Immunogenicity in Phase 2 trial

The Phase 2 clinical trial demonstrated that the anthrax vaccine by GC Biopharma elicited antibodies that neutralised the anthrax toxin at a level exceeding the pre-defined protective threshold. This finding indicates robust immunogenicity and suggests that BARYTHRAX can provide clinically meaningful protection against anthrax infection.

Clinical Trials | 03/11/2025 | By Dineshwori |  119

WINREVAIR from Merck Gains Updated FDA Indication for Pulmonary Arterial Hypertension

Adding WINREVAIR from Merck to background PAH therapy improved exercise capacity and WHO Functional Class (FC), and reduced the risk of clinical worsening events, including hospitalisation for PAH, lung transplantation and death.

Clinical Trials | 29/10/2025 | By Dineshwori |  117

Lilly's Omvoh Shows Early, Sustained Relief in Bowel Urgency for Ulcerative Colitis

Lilly’s Phase 3b LUCENT-URGE results show that Omvoh (mirikizumab-mrkz) provides early and sustained improvements in bowel urgency in ulcerative colitis. The study is the first in inflammatory bowel disease to assess urgency across severity, frequency, and stool deferral time.

Clinical Trials | 28/10/2025 | By Dineshwori |  125

Sanofi's Efdoralprin Alfa Meets Key Goals in Phase-II AATD Emphysema Study

Efdoralprin Alfa was previously granted fast track and Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of AATD Emphysema. It is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

Clinical Trials | 27/10/2025 | By Dineshwori

Boehringer Ingelheim's Zongertinib Shows 77 Percent Response Rate in HER2-Mutant NSCLC

Boehringer Ingelheim presented Phase Ib Beamion LUNG-1 trial data at ESMO 2025, showing that zongertinib achieved a 77 percent Objective Response Rate (ORR) in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC.

Clinical Trials | 24/10/2025 | By Dineshwori |  143

METiS TechBio's AI-Designed Drug MTS-004 Completes Phase III Trial for Pseudobulbar Affect

METiS TechBio, a global leader in AI-driven nanodelivery and formulation innovation, has announced that its small-molecule candidate MTS-004 has successfully met the primary endpoint in its Phase III clinical trial.

Clinical Trials | 24/10/2025 | By Dineshwori |  139

Eli Lilly Reports Positive Phase 3 Topline Results for Oral GLP-1 Orforglipron in Type 2 Diabetes

Eli Lilly and Company has announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials evaluating orforglipron for the treatment of type 2 diabetes.

Clinical Trials | 16/10/2025 | By Dineshwori |  187

Pfizer Reports Positive Phase 3 Results for TUKYSA Combination in First-Line HER2+ Metastatic Breast Cancer

Pfizer has announced positive topline results from its Phase 3 HER2CLIMB-05 trial evaluating TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a first-line maintenance therapy for patients with HER2-positive (HER2+) metastatic breast cancer (MBC).

Clinical Trials | 15/10/2025 | By Dineshwori |  111

AskBio Reports Safety Data from AB-1003 LGMD 2I/R9 Study

Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with Limb-Girdle Muscular Dystrophy (LGMD) 2I/R9, with no dose-limiting toxicities or serious adverse events reported up to 52 weeks post-treatment.

Clinical Trials | 13/10/2025 | By Dineshwori

Lupin to Present Phase 1 Data on LNP3693 (STING agonist) at ESMO Congress 2025

Lupin will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, scheduled to be held from October 17 to October 21, 2025.

Clinical Trials | 13/10/2025 | By Dineshwori |  137